Results at 48 weeks in the TENAYA and LUCERNE phase 3 trials showed positive outcomes of faricimab for neovascular age-related macular degeneration.Dosing intervals were between 12 and 16 weeks in 80% of the patients.“Faricimab is the first bispecific …
Author: Healio ophthalmology
Apellis reports mixed results for pegcetacoplan for geographic atrophy
Apellis Pharmaceuticals reported topline results from two phase 3 studies investigating pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration, according to a press release.DERBY and OAKS are multicenter, random…
Dry eye candidate demonstrates promising results in phase 2b study
AR-15512 achieved statistical significance for multiple sign and symptom endpoints in patients with dry eye disease, according to a press release from Aerie Pharmaceuticals.AR-15512, a TRPM8 agonist, demonstrated positive topline results in COMET-1, a …
Panel: ‘Weak’ evidence supports using medical cannabis to treat chronic pain
An international panel of experts reported that non-inhaled medical cannabis or cannabinoids were associated with modest benefits in patients with chronic pain.Heretofore, most research has focused on the consequences of recreational cannabis use, Jaso…
As telehealth use drops, expert seeks help securing its future
Data from FAIR Health, a nonprofit organization that provides information on health care coverage and insurance, indicate that telehealth use may be dropping after skyrocketing in 2020.According to the organization, the percentage of individual service…
OCT, OCT-A show retinal changes in children recovered from COVID-19
An OCT and OCT-A study of pediatric patients recovered from COVID-19 showed that morphological and vascular structural changes in the macula and optic disc may occur, including in eyes that appear normal on biomicroscopy and fundus exam.“The morphologi…
Glaukos, Ivantis settle patent lawsuit
Glaukos and Ivantis have entered into a settlement agreement to terminate a patent infringement lawsuit concerning the Hydrus microstent, according to company press releases.Ivantis will pay Glaukos $60 million in two installments, $30 million by Dec. …
Q&A: Women in Medicine Summit offers opportunities to network, cultivate change
This year’s Women in Medicine Summit will be held virtually on Sept. 24 to Sept. 25. The conference identifies barriers that women in medicine face and offers solutions to gender inequity.Summit attendees will hear from a diverse group of speakers abou…
VIDEO: Need for remote monitoring will increase with longer-acting drugs
In this video, Anat Loewenstein, MD, MHA, highlights some of the most interesting points of a symposium on remote monitoring of retinal diseases, held during the virtual Euretina congress.Remote monitoring will be needed even more now because longer-ac…
First results with THR-149 show promise in treatment of diabetic macular edema
First results with THR-149, a bicyclic peptide inhibitor that targets plasma kallikrein, showed safety and efficacy in treating patients with diabetic macular edema, according to a specialist speaking at the virtual Euretina congress.“THR-149 is a high…
HHS plan to lower prescription drug costs is a good start, but we need bold, swift action
HHS recently announced a plan supporting legislation that would allow it to negotiate Medicare Part B and Part D drug prices directly with pharmaceutical companies and then make those prices available to other purchasers, in addition to other key polic…
Novel digital therapy for amblyopia demonstrates positive phase 3 results
Luminopia One, an investigational digital therapy that allows patients with amblyopia to watch visually modified TV shows and movies to improve vision, has shown positive results, according to a press release from Luminopia.The phase 3 multicenter, ran…
VIDEO: Novel biologic agent for treatment of non-anterior uveitis under investigation
In this video from the virtual Euretina congress, Quan Dong Nguyen, MD, MSc, speaks about ABY-035, a novel biologic compound that has been demonstrated to be a potent interleukin-17A inhibitor with unique pharmacological properties.ABY-035 (Affibody) i…
GT005 gene therapy shows ability to modulate complement pathway in geographic atrophy
In a first-in-human phase 1/2 study, GT005, an AAV2-based one-time investigational gene therapy, showed potential to regulate the complement pathway involved in the pathogenesis of geographic atrophy.The complement system has a key role in the pathogen…
VIDEO: Euretina Lecture focuses on key role of choriocapillaris in AMD
In his keynote Euretina Lecture, delivered at the virtual Euretina congress, SriniVas Sadda, MD, highlighted the critical role of the choriocapillaris in age-related macular degeneration.Studies with OCT angiography have shown that the choriocapillaris…
FDA: Prescribers can help stop false or misleading prescription drug promotion
It is estimated that the pharmaceutical industry spent more than $24 billion on prescription drug promotion in 2017.Prescription drug promotion can provide prescribers with information about the latest drug therapies and may be part of their decision-m…
AbbVie, Regenxbio to develop, commercialize RGX-314 for retinal diseases
AbbVie and Regenxbio have entered into a partnership to develop and commercialize RGX-314, an investigational gene therapy, for the treatment of retinal diseases, according to a press release.Regenxbio will be responsible for completing ongoing trials,…
WIO meeting items, refractive surgery articles top September coverage
The most-read articles on Healio/OSN so far this month include a link between some medications and acute retinal toxicity and a strong return for refractive corneal surgery.Read these and other recent popular articles below.Newer and some longer-term u…
Cequa, timolol and new lens technologies top recent blog posts
Recent blogs on Healio/OSN include an explanation of patient payments for Cequa and a look at timolol in glaucoma treatment.Read these and other popular blogs below.BLOG: Game on: Cequa jumps into Medicare Part DLadies and gentlemen, we have ourselves …
OCT angiography shows ability to detect subclinical vascular changes in multiple sclerosis
OCT angiography could represent a novel and helpful early biomarker for diagnosing and monitoring multiple sclerosis progression, as shown in a study presented at the virtual Euretina congress.“OCT-A parameters showed retinal vascular abnormalities bef…